{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:08:03Z","timestamp":1787242083056,"version":"build-2736575974"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PE0000006"],"award-info":[{"award-number":["PE0000006"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01893-6","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:53:50Z","timestamp":1763704430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cerebrospinal fluid NPTX2 and [18F]FDG PET track serotonergic vulnerability to neurodegeneration in prodromal Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Federico","family":"Massa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Orso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"De Cesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pelagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Garbarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Raffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Mattioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Argenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Losa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Kreshpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Panza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Bozzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Visigalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Brugnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Girtler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Piana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Arnaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmario","family":"Sambuceti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Uccelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"1893_CR1","doi-asserted-by":"publisher","unstructured":"Jack CR Jr., Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement.\u00a02024. https:\/\/doi.org\/10.1002\/alz.13859.","DOI":"10.1002\/alz.13859"},{"key":"1893_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1893_CR3","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam M-M, Cuello AC, et al. The cholinergic system in the pathophysiology and treatment of alzheimer\u2019s disease. Brain. 2018;141:1917\u201333.","journal-title":"Brain"},{"key":"1893_CR4","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3233\/JAD-160763","volume":"57","author":"R Wang","year":"2016","unstructured":"Wang R, Reddy P, Hemachandra. Role of glutamate and NMDA receptors in alzheimer\u2019s disease. J Alzheimer\u2019s Disease. 2016;57:1041\u20138. https:\/\/doi.org\/10.3233\/JAD-160763.","journal-title":"J Alzheimer\u2019s Disease"},{"key":"1893_CR5","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.neubiorev.2013.05.008","volume":"37","author":"L Trillo","year":"2013","unstructured":"Trillo L, Das D, Hsieh W, et al. Ascending monoaminergic systems alterations in alzheimer\u2019s disease. Translating basic science into clinical care. Neurosci Biobehav Rev. 2013;37:1363\u201379. https:\/\/doi.org\/10.1016\/j.neubiorev.2013.05.008.","journal-title":"Neurosci Biobehav Rev"},{"key":"1893_CR6","doi-asserted-by":"publisher","unstructured":"Saggu S, Bai A, Aida M, et al. Monoamine alterations in alzheimer\u2019s disease and their implications in comorbid neuropsychiatric symptoms. Geroscience. 2024.\u00a0https:\/\/doi.org\/10.1007\/s11357-024-01359-x.","DOI":"10.1007\/s11357-024-01359-x"},{"key":"1893_CR7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/hbm.25244","volume":"42","author":"J Dukart","year":"2021","unstructured":"Dukart J, Holiga S, Rullmann M, et al. JuSpace: A tool for Spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter maps. Hum Brain Mapp. 2021;42:555\u201366. https:\/\/doi.org\/10.1002\/hbm.25244.","journal-title":"Hum Brain Mapp"},{"key":"1893_CR8","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1007\/s00259-023-06132-4","volume":"50","author":"C Boccalini","year":"2023","unstructured":"Boccalini C, Nicastro N, Peretti DE, et al. Sex differences in dementia with lewy bodies: an imaging study of neurotransmission pathways. Eur J Nucl Med Mol Imaging. 2023;50:2036\u201346. https:\/\/doi.org\/10.1007\/s00259-023-06132-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1893_CR9","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1002\/hbm.26206","volume":"44","author":"E Premi","year":"2023","unstructured":"Premi E, Dukart J, Mattioli I, et al. Unravelling neurotransmitters impairment in primary progressive aphasias. Hum Brain Mapp. 2023;44:2245\u201353. https:\/\/doi.org\/10.1002\/hbm.26206.","journal-title":"Hum Brain Mapp"},{"key":"1893_CR10","doi-asserted-by":"publisher","first-page":"106061","DOI":"10.1016\/j.parkreldis.2024.106061","volume":"122","author":"SP Caminiti","year":"2024","unstructured":"Caminiti SP, Galli A, Jonghi-Lavarini L, et al. Mapping brain metabolism, connectivity and neurotransmitters topography in early and late onset dementia with lewy bodies. Parkinsonism Relat Disord. 2024;122:106061. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106061.","journal-title":"Parkinsonism Relat Disord"},{"key":"1893_CR11","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00259-018-4039-7","volume":"45","author":"J Arbizu","year":"2018","unstructured":"Arbizu J, Festari C, Altomare D, et al. Clinical utility of FDG-PET for the clinical diagnosis in MCI. Eur J Nucl Med Mol Imaging. 2018;45:1497\u2013508. https:\/\/doi.org\/10.1007\/s00259-018-4039-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1893_CR12","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00259-018-4030-3","volume":"45","author":"F Nobili","year":"2018","unstructured":"Nobili F, Festari C, Altomare D, et al. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. Eur J Nucl Med Mol Imaging. 2018;45:1557\u201366.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1893_CR13","doi-asserted-by":"publisher","first-page":"6146","DOI":"10.1002\/alz.14096","volume":"20","author":"L Lorenzini","year":"2024","unstructured":"Lorenzini L, Collij LE, Tesi N, et al. Alzheimer\u2019s disease genetic pathways impact cerebrospinal fluid biomarkers and imaging endophenotypes in non-demented individuals. Alzheimer\u2019s Dement. 2024;20:6146\u201360. https:\/\/doi.org\/10.1002\/alz.14096.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1893_CR14","doi-asserted-by":"publisher","unstructured":"Colom-Cadena M, Spires-Jones T, Zetterberg H, et al. The clinical promise of biomarkers of synapse damage or loss in alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12. https:\/\/doi.org\/10.1186\/s13195-020-00588-4.","DOI":"10.1186\/s13195-020-00588-4"},{"key":"1893_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:280\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1893_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1074\/mcp.RA118.001290","volume":"18","author":"A Lle\u00f3","year":"2019","unstructured":"Lle\u00f3 A, N\u00fa\u00f1ez-Llaves R, Alcolea D, et al. Changes in synaptic proteins precede neurodegeneration markers in preclinical alzheimer\u2019s disease cerebrospinal fluid*. Mol Cell Proteomics. 2019;18:546\u201360. https:\/\/doi.org\/10.1074\/mcp.RA118.001290.","journal-title":"Mol Cell Proteomics"},{"key":"1893_CR17","first-page":"789","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ. Alzheimer\u2019s disease is a synaptic failure. Sci (1979). 2002;298:789\u201391.","journal-title":"Sci (1979)"},{"key":"1893_CR18","doi-asserted-by":"publisher","first-page":"117727192095031","DOI":"10.1177\/1177271920950319","volume":"15","author":"E Camporesi","year":"2020","unstructured":"Camporesi E, Nilsson J, Brinkmalm A, et al. Fluid biomarkers for synaptic dysfunction and loss. Biomark Insights. 2020;15:1177271920950319. https:\/\/doi.org\/10.1177\/1177271920950319.","journal-title":"Biomark Insights"},{"key":"1893_CR19","doi-asserted-by":"publisher","first-page":"e2065","DOI":"10.1212\/WNL.0000000000012853","volume":"97","author":"M Mil\u00e0-Alom\u00e0","year":"2021","unstructured":"Mil\u00e0-Alom\u00e0 M, Brinkmalm A, Ashton NJ, et al. CSF synaptic biomarkers in the preclinical stage of alzheimer disease and their association with MRI and PET. Neurology. 2021;97:e2065. https:\/\/doi.org\/10.1212\/WNL.0000000000012853.","journal-title":"Neurology"},{"key":"1893_CR20","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/WNL.0000000000002423","volume":"86","author":"H Wellington","year":"2016","unstructured":"Wellington H, Paterson RW, Portelius E, et al. Increased CSF neurogranin concentration is specific to alzheimer disease. Neurology. 2016;86:829\u201335. https:\/\/doi.org\/10.1212\/WNL.0000000000002423.","journal-title":"Neurology"},{"key":"1893_CR21","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/brain\/awv267","volume":"138","author":"E Portelius","year":"2015","unstructured":"Portelius E, Zetterberg H, Skillb\u00e4ck T, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in alzheimer\u2019s disease. Brain. 2015;138:3373\u201385. https:\/\/doi.org\/10.1093\/brain\/awv267.","journal-title":"Brain"},{"key":"1893_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.neurobiolaging.2022.03.019","volume":"117","author":"F Massa","year":"2022","unstructured":"Massa F, Halbgebauer S, Barba L, et al. Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to alzheimer\u2019s disease: preliminary data. Neurobiol Aging. 2022;117:212\u201321. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2022.03.019.","journal-title":"Neurobiol Aging"},{"key":"1893_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-021-02411-2","author":"N G\u00f3mez de San Jos\u00e9","year":"2021","unstructured":"G\u00f3mez de San Jos\u00e9 N, Massa F, Halbgebauer S, et al. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. J Neural Transm. 2021. https:\/\/doi.org\/10.1007\/s00702-021-02411-2.","journal-title":"J Neural Transm"},{"key":"1893_CR24","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00415-023-12154-7","volume":"271","author":"F Massa","year":"2024","unstructured":"Massa F, Martinuzzo C, de G\u00f3mez N, et al. Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to alzheimer\u2019s disease. J Neurol. 2024;271:1999\u20132009. https:\/\/doi.org\/10.1007\/s00415-023-12154-7.","journal-title":"J Neurol"},{"key":"1893_CR25","doi-asserted-by":"publisher","unstructured":"Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90. https:\/\/doi.org\/10.1136\/jnnp-2018-320106.","DOI":"10.1136\/jnnp-2018-320106"},{"key":"1893_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H, Skillb\u00e4ck T, Mattsson N, et al. Association of cerebrospinal fluid neurofilament light concentration with alzheimer disease progression. JAMA Neurol. 2016;73:60\u20137. https:\/\/doi.org\/10.1001\/jamaneurol.2015.3037.","journal-title":"JAMA Neurol"},{"key":"1893_CR27","doi-asserted-by":"publisher","first-page":"e12005","DOI":"10.1002\/dad2.12005","volume":"12","author":"K Dhiman","year":"2020","unstructured":"Dhiman K, Gupta VB, Villemagne VL, et al. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in alzheimer\u2019s disease. Alzheimer\u2019s Dementia: Diagnosis Assess Disease Monit. 2020;12:e12005. https:\/\/doi.org\/10.1002\/dad2.12005.","journal-title":"Alzheimer\u2019s Dementia: Diagnosis Assess Disease Monit"},{"key":"1893_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14:535\u201362.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1893_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/joim.12190","volume":"275","author":"RC Petersen","year":"2014","unstructured":"Petersen RC, Caracciolo B, Brayne C, et al. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014;275:214\u201328. https:\/\/doi.org\/10.1111\/joim.12190.","journal-title":"J Intern Med"},{"key":"1893_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S1474-4422(23)00447-7","volume":"23","author":"GB Frisoni","year":"2024","unstructured":"Frisoni GB, Festari C, Massa F, et al. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. Lancet Neurol. 2024;23:302\u201312. https:\/\/doi.org\/10.1016\/S1474-4422(23)00447-7.","journal-title":"Lancet Neurol"},{"key":"1893_CR31","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00259-021-05603-w","volume":"49","author":"E Guedj","year":"2022","unstructured":"Guedj E, Varrone A, Boellaard R, et al. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022;49:632\u201351. https:\/\/doi.org\/10.1007\/s00259-021-05603-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1893_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.neuroimage.2012.07.001","volume":"63","author":"M Savli","year":"2012","unstructured":"Savli M, Bauer A, Mitterhauser M, et al. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. NeuroImage. 2012;63:447\u201359. https:\/\/doi.org\/10.1016\/j.neuroimage.2012.07.001.","journal-title":"NeuroImage"},{"key":"1893_CR33","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41593-022-01186-3","volume":"25","author":"JY Hansen","year":"2022","unstructured":"Hansen JY, Shafiei G, Markello RD, et al. Mapping neurotransmitter systems to the structural and functional organization of the human neocortex. Nat Neurosci. 2022;25:1569\u201381. https:\/\/doi.org\/10.1038\/s41593-022-01186-3.","journal-title":"Nat Neurosci"},{"key":"1893_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neulet.2019.03.050","volume":"704","author":"S Chakraborty","year":"2019","unstructured":"Chakraborty S, Lennon JC, Malkaram SA, et al. Serotonergic system, cognition, and BPSD in alzheimer\u2019s disease. Neurosci Lett. 2019;704:36\u201344. https:\/\/doi.org\/10.1016\/j.neulet.2019.03.050.","journal-title":"Neurosci Lett"},{"key":"1893_CR35","doi-asserted-by":"publisher","unstructured":"Rubin RD, Watson PD, Duff MC, Cohen NJ. The role of the hippocampus in flexible cognition and social behavior. Front Hum Neurosci. 2014;8. https:\/\/doi.org\/10.3389\/fnhum.2014.00742.","DOI":"10.3389\/fnhum.2014.00742"},{"key":"1893_CR36","doi-asserted-by":"publisher","unstructured":"Glikmann-Johnston Y, Saling MM, Reutens DC, Stout JC. Hippocampal 5-HT1A receptor and Spatial learning and memory. Front Pharmacol. 2025;6. https:\/\/doi.org\/10.3389\/fphar.2015.00289.","DOI":"10.3389\/fphar.2015.00289"},{"key":"1893_CR37","doi-asserted-by":"publisher","unstructured":"Robbins TW. From arousal to cognition: the integrative position of the prefrontal cortex. Progress in brain research. Elsevier; 2000. pp. 469\u201383. https:\/\/doi.org\/10.1016\/S0079-6123(00)26030-5.","DOI":"10.1016\/S0079-6123(00)26030-5"},{"key":"1893_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0278-2626(03)00284-7","volume":"55","author":"L Clark","year":"2004","unstructured":"Clark L, Cools R, Robbins TW. The neuropsychology of ventral prefrontal cortex: Decision-making and reversal learning. Brain Cogn. 2004;55:41\u201353. https:\/\/doi.org\/10.1016\/S0278-2626(03)00284-7.","journal-title":"Brain Cogn"},{"key":"1893_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0006-8993(03)02554-X","volume":"974","author":"MKP Lai","year":"2003","unstructured":"Lai MKP, Tsang SWY, Francis PT, et al. Reduced serotonin 5-HT1A receptor binding in the Temporal cortex correlates with aggressive behavior in alzheimer disease. Brain Res. 2003;974:82\u20137. https:\/\/doi.org\/10.1016\/S0006-8993(03)02554-X.","journal-title":"Brain Res"},{"key":"1893_CR40","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S0893-133X(00)00227-X","volume":"24","author":"J Tauscher","year":"2001","unstructured":"Tauscher J, Verhoeff NPLG, Christensen BK, et al. Serotonin 5-HT1A receptor binding potential declines with age as measured by [11\u00a0C]WAY-100635 and PET. Neuropsychopharmacology. 2001;24:522\u201330. https:\/\/doi.org\/10.1016\/S0893-133X(00)00227-X.","journal-title":"Neuropsychopharmacology"},{"key":"1893_CR41","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1073\/pnas.0510237103","volume":"103","author":"V Kepe","year":"2006","unstructured":"Kepe V, Barrio JR, Huang S-C, et al. Serotonin 1A receptors in the living brain of alzheimer\u2019s disease patients. Proc Natl Acad Sci. 2006;103:702\u20137. https:\/\/doi.org\/10.1073\/pnas.0510237103.","journal-title":"Proc Natl Acad Sci"},{"key":"1893_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1440-1789.2010.01193.x","volume":"31","author":"K Mizukami","year":"2011","unstructured":"Mizukami K, Ishikawa M, Akatsu H, et al. An immunohistochemical study of the serotonin 1A receptor in the hippocampus of subjects with alzheimer\u2019s disease. Neuropathology. 2011;31:503\u20139. https:\/\/doi.org\/10.1111\/j.1440-1789.2010.01193.x.","journal-title":"Neuropathology"},{"key":"1893_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3389\/fnagi.2019.00175","volume":"11","author":"X Pan","year":"2019","unstructured":"Pan X, Kaminga AC, Wen SW, Wu X, Acheampong K, Liu A. Dopamine and dopamine receptors in Alzheimer\u2019s disease: a systematic review and network meta-analysis. Front Aging Neurosci. 2019;11:175. https:\/\/doi.org\/10.3389\/fnagi.2019.00175.","journal-title":"Front Aging Neurosci"},{"key":"1893_CR44","doi-asserted-by":"publisher","unstructured":"Zhang Y, Liang Y, Gu Y. The dopaminergic system and Alzheimer\u2019s disease. Neural Regen Res. 2025;20. https:\/\/doi.org\/10.4103\/NRR.NRR-D-24-00230.","DOI":"10.4103\/NRR.NRR-D-24-00230"},{"key":"1893_CR45","doi-asserted-by":"publisher","unstructured":"Kumar A, Dhull DK, Mishra PS. Therapeutic potential of mGluR5 targeting in alzheimer\u2019s disease. Front Neurosci. 2015;9. https:\/\/doi.org\/10.3389\/fnins.2015.00215.","DOI":"10.3389\/fnins.2015.00215"},{"key":"1893_CR46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2174\/1570159X19666210916102638","volume":"21","author":"KS Abd-Elrahman","year":"2021","unstructured":"Abd-Elrahman KS, Sarasija S, Ferguson SSG. The role of neuroglial metabotropic glutamate receptors in alzheimer\u2019s disease. Curr Neuropharmacol. 2021;21:273\u201383. https:\/\/doi.org\/10.2174\/1570159X19666210916102638.","journal-title":"Curr Neuropharmacol"},{"key":"1893_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/alzrt175","volume":"5","author":"T Chalermpalanupap","year":"2013","unstructured":"Chalermpalanupap T, Kinkead B, Hu WT, et al. Targeting norepinephrine in mild cognitive impairment and alzheimer\u2019s disease. Alzheimers Res Ther. 2013;5:21. https:\/\/doi.org\/10.1186\/alzrt175.","journal-title":"Alzheimers Res Ther"},{"key":"1893_CR48","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.brainres.2018.01.001","volume":"1702","author":"M Gannon","year":"2019","unstructured":"Gannon M, Wang Q. Complex noradrenergic dysfunction in alzheimer\u2019s disease: low norepinephrine input is not always to blame. Brain Res. 2019;1702:12\u20136. https:\/\/doi.org\/10.1016\/j.brainres.2018.01.001.","journal-title":"Brain Res"},{"key":"1893_CR49","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1093\/brain\/awz193","volume":"142","author":"MJ Betts","year":"2019","unstructured":"Betts MJ, Kirilina E, Otaduy MCG, et al. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain. 2019;142:2558\u201371. https:\/\/doi.org\/10.1093\/brain\/awz193.","journal-title":"Brain"},{"key":"1893_CR50","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.semcdb.2021.01.005","volume":"116","author":"J Jim\u00e9nez-Balado","year":"2021","unstructured":"Jim\u00e9nez-Balado J, Eich TS. GABAergic dysfunction, neural network hyperactivity and memory impairments in human aging and alzheimer\u2019s disease. Semin Cell Dev Biol. 2021;116:146\u201359. https:\/\/doi.org\/10.1016\/j.semcdb.2021.01.005.","journal-title":"Semin Cell Dev Biol"},{"key":"1893_CR51","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/bies.201500004","volume":"37","author":"MA Busche","year":"2015","unstructured":"Busche MA, Konnerth A. Neuronal hyperactivity \u2013 A key defect in alzheimer\u2019s disease? BioEssays. 2015;37:624\u201332. https:\/\/doi.org\/10.1002\/bies.201500004.","journal-title":"BioEssays"},{"key":"1893_CR52","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.neubiorev.2004.08.008","volume":"28","author":"Y Sari","year":"2004","unstructured":"Sari Y. Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev. 2004;28:565\u201382. https:\/\/doi.org\/10.1016\/j.neubiorev.2004.08.008. https:\/\/doi.org\/https:\/\/doi.org\/.","journal-title":"Neurosci Biobehav Rev"},{"key":"1893_CR53","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/sj.npp.1300330","volume":"29","author":"M Garcia-Alloza","year":"2004","unstructured":"Garcia-Alloza M, Hirst WD, Chen CPL-H, et al. Differential involvement of 5-HT1B\/1D and 5-HT6 receptors in cognitive and Non-cognitive symptoms in alzheimer\u2019s disease. Neuropsychopharmacology. 2004;29:410\u20136. https:\/\/doi.org\/10.1038\/sj.npp.1300330.","journal-title":"Neuropsychopharmacology"},{"key":"1893_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26725","author":"A Soldan","year":"2023","unstructured":"Soldan A, Oh S, Ryu T, et al. NPTX2 in cerebrospinal fluid predicts the progression from normal cognition to mild cognitive impairment. Ann Neurol n\/a. 2023. https:\/\/doi.org\/10.1002\/ana.26725.","journal-title":"Ann Neurol n\/a"},{"key":"1893_CR55","doi-asserted-by":"publisher","first-page":"e23798","DOI":"10.7554\/eLife.23798","volume":"6","author":"M-F Xiao","year":"2017","unstructured":"Xiao M-F, Xu D, Craig MT, et al. NPTX2 and cognitive dysfunction in alzheimer\u2019s disease. Elife. 2017;6:e23798. https:\/\/doi.org\/10.7554\/eLife.23798.","journal-title":"Elife"},{"key":"1893_CR56","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1002\/alz.12353","volume":"17","author":"O Libiger","year":"2021","unstructured":"Libiger O, Shaw LM, Watson MH, et al. Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2021;17:1976\u201387. https:\/\/doi.org\/10.1002\/alz.12353.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1893_CR57","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41386-018-0091-z","volume":"43","author":"S Chang","year":"2018","unstructured":"Chang S, Bok P, Tsai C-Y, et al. NPTX2 is a key component in the regulation of anxiety. Neuropsychopharmacology. 2018;43:1943\u201353. https:\/\/doi.org\/10.1038\/s41386-018-0091-z.","journal-title":"Neuropsychopharmacology"},{"key":"1893_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.brainres.2010.03.004","volume":"1328","author":"L Bjartmar","year":"2010","unstructured":"Bjartmar L, Alkhori L, Ruud J, et al. Long-term treatment with antidepressants, but not environmental stimulation, induces expression of NP2 mRNA in hippocampus and medial Habenula. Brain Res. 2010;1328:25\u201333. https:\/\/doi.org\/10.1016\/j.brainres.2010.03.004.","journal-title":"Brain Res"},{"key":"1893_CR59","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cell.2014.11.047","volume":"160","author":"Y Yan","year":"2015","unstructured":"Yan Y, Jiang W, Liu L, et al. Dopamine controls systemic inflammation through Inhibition of NLRP3 inflammasome. Cell. 2015;160:62\u201373. https:\/\/doi.org\/10.1016\/j.cell.2014.11.047. https:\/\/doi.org\/https:\/\/doi.org\/.","journal-title":"Cell"},{"key":"1893_CR60","doi-asserted-by":"publisher","unstructured":"Heneka MT, Nadrigny F, Regen T, et al. Locus ceruleus controls Alzheimer\u2019s disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci. 2010;107:6058\u201363. https:\/\/doi.org\/10.1073\/pnas.0909586107.","DOI":"10.1073\/pnas.0909586107"},{"key":"1893_CR61","doi-asserted-by":"publisher","unstructured":"Turkin A, Tuchina O, Klempin F. Microglia function on precursor cells in the adult hippocampus and their responsiveness to serotonin signaling. Front Cell Dev Biol. 2021;9. https:\/\/doi.org\/10.3389\/fcell.2021.665739.","DOI":"10.3389\/fcell.2021.665739"},{"key":"1893_CR62","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak A, Foschi M, Abu-Rumeileh S, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18:158\u201372. https:\/\/doi.org\/10.1038\/s41582-021-00616-3.","journal-title":"Nat Rev Neurol"},{"key":"1893_CR63","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1093\/brain\/awae211","volume":"147","author":"DE Peretti","year":"2024","unstructured":"Peretti DE, Boccalini C, Ribaldi F, et al. Association of glial fibrillary acid protein, alzheimer\u2019s disease pathology and cognitive decline. Brain. 2024;147:4094\u2013104. https:\/\/doi.org\/10.1093\/brain\/awae211.","journal-title":"Brain"},{"key":"1893_CR64","doi-asserted-by":"publisher","first-page":"16065","DOI":"10.1038\/nrdp.2016.65","volume":"2","author":"C Otte","year":"2016","unstructured":"Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2:16065. https:\/\/doi.org\/10.1038\/nrdp.2016.65.","journal-title":"Nat Rev Dis Primers"},{"key":"1893_CR65","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1111\/ene.14412","volume":"27","author":"KS Frederiksen","year":"2020","unstructured":"Frederiksen KS, Cooper C, Frisoni GB, et al. A European academy of neurology guideline on medical management issues in dementia. Eur J Neurol. 2020;27:1805\u201320. https:\/\/doi.org\/10.1111\/ene.14412.","journal-title":"Eur J Neurol"},{"key":"1893_CR66","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3233\/JAD-150181","volume":"49","author":"D Bensamoun","year":"2015","unstructured":"Bensamoun D, Guignard R, Furst AJ, et al. Associations between neuropsychiatric symptoms and cerebral amyloid deposition in cognitively impaired elderly people. J Alzheimer\u2019s Disease. 2015;49:387\u201398. https:\/\/doi.org\/10.3233\/JAD-150181.","journal-title":"J Alzheimer\u2019s Disease"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01893-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01893-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01893-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:15:14Z","timestamp":1767032114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01893-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1893"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01893-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research involves human participants and was approved by the regional ethical committee (Comitato Etico Regionale della Liguria, study ref: PNRR-POC-2022-12376726). Informed consent was obtained from all participants. Anonymized data published per hospital rules for retrospective data collected during the clinical routine. All procedures followed the 1964 Helsinki declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}